Recurrent PD-L1+ Malignant Tumors
1 clinical trials · Condition
◉ Watch Recurrent PD-L1+ Malignant Tumors
| Record | Firm | Date |
|---|---|---|
| Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors (NCT02930967) | China Meitan General Hospital | 2016-08-01 |
Track Recurrent PD-L1+ Malignant Tumors automatically
Every clearance here is in the API, with alerts when new ones post.